

Test Description

The MolQ Liquid Precision Panel includes 50 genes, involving hotspot regions and 3159 unique variants, applicable to a wide range of tumor types for detection of SNV (single and multiple nucleotide variation), Insertion-Deletion, Copy Number Variation (CNV), and gene Fusions. Fusion and splice variants are detected in RNA.

Patient Demographic

Name: Ms. Megha Kalyan
Sex: Female
Date of Birth/Age: 41 years
Disease: Lung Adenocarcinoma

Clinician

Clinician Name: Dr Amit Verma
Medical Facility: Dr AV Institute of Personalized Cancer Therapy and Research
Pathologist: Not Provided

Specimen

Booking ID: 012305180274
Sample Type: Blood
Tumor Content Percentage: NA
Date of Collection: 18-05-2023
Date of Booking: 18-05-2023

CLINICAL SYNOPSIS

Megha Kalyan, is a known case of lung adenocarcinoma. He has been evaluated for pathogenic variations in the genes listed in Appendix 2.

RESULT SUMMARY

The average coverage of sequencing was 25474 in the given specimen. The assay detected clinically significant *EGFR* (p.Glu746_750del, VAF=2.78%) and *KRAS* (p.Gln61Lys, VAF=0.62%) variants in this sample.

"Important Disclaimer: The concentration of cfDNA/cfTNA was less in the given specimen. NGS test was performed on a lower amount than the standard requirement of 20 ng."

RESULTS

Variants in *KRAS* and *EGFR* genes were detected.

Gene/ Transcript (Locus)	Variant ID	Variant	Allele Frequency	Variant Effect	*Relevant Therapies (In this cancer type)	(In other cancer type)	Tier ¹
<i>KRAS</i> NM_033360.4 (chr12:25380277)	COSM87298	c.180_181delTCinsAA (p.Gly60=;Gln61Lys)	0.62%	Synonymous, Missense	None	bevacizumab + chemotherapy	IIc
<i>EGFR</i> NM_005228.5 (chr7:55242465)	COSM6225	c.2236_2250delGAAT TAAGAGAAGCA (p.Glu746_Ala750del)	2.78%	Non frame shift Deletion	Afatinib ^{i,ii} bevacizumab* + erlotinib ⁱⁱ dacomitinib ^{i,ii} erlotinib ^{i,ii} erlotinib + ramucirumab ^{i,ii} gefitinib* ^{i,ii} osimertinib ^{i,ii} atezolizumab + bevacizumab +chemotherapy gefitinib + chemotherapy	None	Ia

* Public data sources included in relevant therapies: FDAⁱ, NCCN, EMAⁱⁱ, ESMO

RELEVANT LUNG CANCER FINDINGS

Gene	Findings	Gene	Findings	Gene	Findings
<i>ALK</i>	None detected	<i>KRAS</i>	c.180_181delTCinsAA; p.Gln61Lys	<i>NTRK3</i>	None detected
<i>BRAF</i>	None detected	<i>MET</i>	None detected	<i>RET</i>	None detected
<i>EGFR</i>	Exon 19 deletion	<i>NTRK1</i>	None detected	<i>ROS1</i>	None detected
<i>ERBB2</i>	None detected	<i>NTRK2</i>	None detected		

CLINICAL CORRELATION AND VARIANT INTERPRETATION

***KRAS* p.Gln61Lys**

Gene description: The *KRAS* proto-oncogene encodes a GTPase that functions in signal transduction and is a member of the *RAS* superfamily which also includes *NRAS* and *HRAS*. *RAS* proteins mediate the transmission of growth signals from the cell surface to the nucleus via the PI3K/AKT/MTOR and RAS/RAF/MEK/ERK pathways, which regulate cell division, differentiation, and survival²⁻⁴.

Alterations and prevalence: Recurrent mutations in *RAS* oncogenes cause constitutive activation and are found in 20-30% of cancers. *KRAS* mutations are observed in up to 10-20% of uterine cancer, 30-35% of lung adenocarcinoma and colorectal cancer, and about 60% of pancreatic cancer⁵. The majority of *KRAS* mutations consist of point mutations occurring at G12, G13, and Q61⁵⁻⁷. Mutations at A59, K117, and A146 have also been observed but are less frequent^{8,9}.

Potential relevance: The FDA has approved the small molecule inhibitors, sotorasib¹⁰ (2021) and adagrasib¹¹ (2022), for the treatment of adult patients with *KRAS* G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). The FDA has also granted breakthrough therapy designation (2022) to the *KRAS* G12C inhibitor, GDC-6036¹², for *KRAS* G12C mutation in non-small cell lung cancer. The small molecular inhibitor, RO-5126766, was granted breakthrough designation (2021) alone for *KRAS* G12V mutant non-small cell lung cancer or in combination with defactinib, for *KRAS* mutant endometrial carcinoma and *KRAS* G12V mutant non-small cell lung cancer¹³. The PLK1 inhibitor, onvansertib¹⁴, was granted fast track designation (2020) in combination with bevacizumab and FOLFIRI for second-line treatment of patients with *KRAS*-mutated metastatic colorectal cancer (mCRC). Additionally, the SHP2 inhibitor, BBP-398¹⁵ was granted fast-track designation (2022) in combination with sotorasib for previously treated patients with *KRAS* G12C-mutated metastatic NSCLC. The EGFR antagonists, cetuximab¹⁶ and panitumumab¹⁷, are contraindicated for treatment of colorectal cancer patients with *KRAS* mutations in exon 2 (codons 12 and 13), exon 3 (codons 59 and 61), and exon 4 (codons 117 and 146)⁹. Additionally, *KRAS* mutations are associated with poor prognosis in NSCLC¹⁸.

***EGFR* p.Glu746_Ala750del (Exon 19 deletion)**

Gene description: The *EGFR* gene encodes the epidermal growth factor receptor (EGFR) tyrosine kinase, a member of the ERBB/human epidermal growth factor receptor (HER) family. In addition to EGFR/ERBB1/HER1, other members of the ERBB/HER family include ERBB2/HER2, ERBB3/HER3, and ERBB4/HER4¹⁹. EGFR ligand induced dimerization results in kinase activation and leads to stimulation of oncogenic signaling pathways including the PI3K/AKT/MTOR and RAS/RAF/MEK/ERK pathways. Activation of these pathways promote cell proliferation, differentiation, and survival^{20,21}.


Alterations and prevalence: Recurrent somatic mutations in the tyrosine kinase domain (TKD) of *EGFR* are observed in approximately 10-20% of lung adenocarcinoma, and at higher frequencies in never-smoker, female, and Asian populations^{5,8,22,23}. The most common mutations occur near the ATP-binding pocket of the TKD and include short in-frame deletions in exon 19 (*EGFR* exon 19 deletion) and the L858R amino acid substitution in exon 21²⁴. These mutations constitutively

activate EGFR resulting in downstream signaling, and represent 80% of the *EGFR* mutations observed in lung cancer. A second group of less prevalent activating mutations include E709K, G719X, S768I, L861Q, and short in-frame insertion mutations in exon 20²⁵⁻²⁸. *EGFR* activating mutations in lung cancer tend to be mutually exclusive to *KRAS* activating mutations²⁹. In contrast, a different set of recurrent activating *EGFR* mutations in the extracellular domain include R108K, A289V and G598V and are primarily observed in glioblastoma^{24,30}. Amplification of EGFR is observed in several cancer types including 30% of glioblastoma, 12% of esophageal cancer, 10% of head and neck cancer, 5% of bladder cancer, and 5% of lung squamous cell carcinoma^{5,8,23,30,31}. Deletion of exons 2-7, encoding the extracellular domain of *EGFR* (EGFRvIII), results in overexpression of a ligand-independent constitutively active protein and is observed in approximately 30% of glioblastoma³²⁻³⁴.

Potential relevance: Approved first-generation EGFR tyrosine kinase inhibitors (TKIs) include erlotinib³⁵ (2004) and gefitinib³⁶ (2015), which block the activation of downstream signaling by reversible interaction with the ATP-binding site. Although initially approved for advanced lung cancer, the discovery that drug sensitivity was associated with exon 19 and exon 21 activating mutations allowed first-generation TKIs to become subsequently approved for front-line therapy in lung cancer tumors containing exon 19 or exon 21 activating mutations. Second-generation TKIs afatinib³⁷ (2013) and dacomitinib³⁸ (2018) bind EGFR and other ERBB/HER gene family members irreversibly and were subsequently approved. First- and second-generation TKIs afatinib, dacomitinib, erlotinib, and gefitinib are recommended for the treatment NSCLC harboring *EGFR* exon 19 insertions, exon 19 deletions, point mutations L861Q, L858R, S768I, and codon 719 mutations, whereas most *EGFR* exon 20 insertions, except p.A763_Y764insFQEA, confer resistance to the same therapies³⁹⁻⁴². However, in 2021, the irreversible tyrosine kinase inhibitor, mobocertinib⁴³ was FDA approved for the treatment of NSCLC with *EGFR* exon 20 insertion mutations. Additionally, in 2022, the FDA granted breakthrough therapy designation to the irreversible EGFR inhibitors, CLN-081 (TPC-064)⁴⁴ and sunvozertinib⁴⁵, for locally advanced or metastatic non-small cell lung cancer harboring *EGFR* exon 20 insertion mutations. In lung cancer containing *EGFR* exon 19 or 21 activating mutations, treatment with TKIs is eventually associated with the emergence of drug resistance⁴⁶. The primary resistance mutation that emerges following treatment with first-generation TKI is T790M, accounting for 50-60% of resistant cases²⁴. Third generation TKIs were developed to maintain sensitivity in the presence of T790M. Osimertinib⁴⁷ (2015) is an irreversible inhibitor indicated for metastatic *EGFR* T790M positive lung cancer and for the first-line treatment of metastatic NSCLC containing *EGFR* exon 19 deletions or exon 21 L858R mutations. Like first-generation TKIs, treatment with osimertinib is associated with acquired resistance. In this case, resistance is associated with the C797S mutation and occurs in 22-44% of cases⁴⁶. The T790M and C797S mutations may be each selected following sequential treatment with a first-generation TKI followed by a third-generation TKI or vice versa⁴⁸. T790M and C797S can occur in either cis or trans allelic orientation⁴⁸. If C797S is observed following progression after treatment with a third-generation TKI in the first-line setting, sensitivity may be retained to first-generation TKIs⁴⁸. If C797S co-occurs in trans with T790M following sequential treatment with first- and third-generation TKIs, patients may exhibit sensitivity to combination first- and third-generation TKIs, but resistance to third-generation TKIs alone^{48,49}. However, C797S occurring in cis conformation with T790M, confers resistance to first- and third-generation TKIs⁴⁸. Fourth-generation TKIs are in development to overcome acquired C797S and T790M resistance mutations after osimertinib treatment. EGFR targeting antibodies including cetuximab (2004), panitumumab (2006), and necitumumab (2016) are under investigation in combination with EGFR-targeting TKIs for efficacy against *EGFR* mutations. The bispecific antibody, amivantamab⁵⁰, targeting EGFR and MET was approved (2021) NSCLC tumors harboring *EGFR* exon 20 insertion mutations. The Oncoprex immunogene therapy quaratusugene ozeplasmid⁵¹ in combination with osimertinib received a fast-track designation from the FDA (2020) for NSCLC tumors harboring *EGFR* mutations that progressed on osimertinib alone. BDTX-189⁵² was granted a fast-track designation (2020) for the treatment of solid tumors harboring an *EGFR* exon 20 insertion mutation.

RECOMMENDATIONS

- Validation of the variant(s) by Sanger sequencing is recommended to rule out false positives.
- Genetic counselling is advised for interpretation on the consequences of the variant(s).
- If results obtained do not match the clinical findings, additional testing should be considered as per referring clinician's recommendations.



MolQ Laboratory (A Unit of Molecular Quest Healthcare Pvt. Ltd.)

Reference Laboratory: 28-29, Sector-18 (P) | Gurgaon, Haryana, 122015 | Phone 0124 - 4307906, Fax 0124 - 4278596 | Email: contact@molq.in

Jatinder Kaur, PhD
Head, Molecular Biology & Genomics

Dr. Gulshan Yadav, MD
Head, Pathology

REFERENCES

1. Li et al. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. *J Mol Diagn.* 2017 Jan;19(1):4-23.
2. Pylyayeva-Gupta et al. RAS oncogenes: weaving a tumorigenic web. *Nat. Rev. Cancer.* 2011 Oct 13;11(11):761-74. PMID: 21993244
3. Karnoub et al. Ras oncogenes: split personalities. *Nat. Rev. Mol. Cell Biol.* 2008 Jul;9(7):517-31. PMID: 18568040
4. Scott et al. Therapeutic Approaches to RAS Mutation. *Cancer J.* 2016 May-Jun;22(3):165-74. doi: 10.1097/PPO.000000000000187. PMID: 27341593
5. Weinstein et al. The Cancer Genome Atlas Pan-Cancer analysis project. *Nat. Genet.* 2013 Oct;45(10):1113-20. PMID: 24071849
6. Román et al. KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target. *Mol Cancer.* 2018 Feb 19;17(1):33. doi: 10.1186/s12943-018-0789-x. PMID: 29455666
7. Dinu et al. Prognostic significance of KRAS gene mutations in colorectal cancer--preliminary study. *J Med Life.* 2014 Oct-Dec;7(4):581-7. PMID: 25713627
8. Cerami et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov.* 2012 May;2(5):401-4. PMID: 22588877
9. Allegra et al. Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. *J. Clin. Oncol.* 2016 Jan 10;34(2):179-85. PMID: 26438111
10. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214665s003lbl.pdf
11. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/2163400orig1s000Corrected_lbl.pdf
12. <https://assets.cwp.roche.com/f/126832/x/5738a7538b/irp230202.pdf>
13. <https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-reports-third-quarter-2022-financial-results>
14. <https://cardiffoncology.investorroom.com/2020-05-28-Cardiff-Oncology-Announces-Fast-Track-Designation-Granted-by-the-FDA-to-Onvansertib-for-Second-Line-Treatment-of-KRAS-Mutated-Colorectal-Cancer>
15. <https://bridgebio.com/news/bridgebio-pharma-announces-first-lung-cancer-patient-dosed-in-phase-1-2-trial-and-us-fda-fast-track-designation-for-shp2-inhibitor-bbp-398-in-combination-with-amgens-lumakras-sotorasib/>
16. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf
17. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf
18. Slebos et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. *N. Engl. J. Med.* 1990 Aug 30;323(9):561-5. PMID: 2199829
19. King et al. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. *Science.* 1985 Sep 6;229(4717):974-6. PMID: 2992089
20. Zhixiang. ErbB Receptors and Cancer. *Methods Mol. Biol.* 2017;1652:3-35. PMID: 28791631
21. Gutierrez et al. HER2: biology, detection, and clinical implications. *Arch. Pathol. Lab. Med.* 2011 Jan;135(1):55-62. PMID: 21204711
22. Pines et al. Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy. *FEBS Lett.* 2010 Jun 18;584(12):2699-706. PMID: 20388509
23. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. *Nature.* 2014 Jul 31;511(7511):543-50. doi: 10.1038/nature13385. Epub 2014 Jul 9. PMID: 25079552
24. da et al. EGFR mutations and lung cancer. *Annu Rev Pathol.* 2011;6:49-69. doi: 10.1146/annurev-pathol-011110-130206. PMID: 20887192
25. Arcila et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. *Mol. Cancer Ther.* 2013 Feb;12(2):220-9. PMID: 23371856
26. Kobayashi et al. EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs. *Clin Cancer Res.* 2015 Dec 1;21(23):5305-13. doi: 10.1158/1078-0432.CCR-15-1046. Epub 2015 Jul 23. PMID: 26206867
27. Yasuda et al. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. *Sci Transl Med.* 2013 Dec 18;5(216):216ra177. PMID: 24353160
28. Chiu et al. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations. *J Thorac Oncol.* 2015 May;10(5):793-9. PMID: 25668120
29. Karachaliou et al. KRAS mutations in lung cancer. *Clin Lung Cancer.* 2013 May;14(3):205-14. PMID: 23122493
30. Brennan et al. The somatic genomic landscape of glioblastoma. *Cell.* 2013 Oct 10;155(2):462-77. PMID: 24120142
31. Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. *Nature.* 2015 Jan 29;517(7536):576-82. PMID: 25631445
32. Mitsudomi et al. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. *FEBS J.* 2010 Jan;277(2):301-8. PMID: 19922469
33. Gazdar. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. *Oncogene.* 2009 Aug;28 Suppl 1:S24-31. PMID: 19680293
34. Gan et al. The EGFRvIII variant in glioblastoma multiforme. *J Clin Neurosci.* 2009 Jun;16(6):748-54. PMID: 19324552
35. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf
36. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf
37. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf
38. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211288s003lbl.pdf
39. NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 2.2023]
40. Naidoo et al. Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib. *Cancer.*

MolQ Laboratory (A Unit of Molecular Quest Healthcare Pvt. Ltd.)

Reference Laboratory: 28-29, Sector-18 (P) | Gurgaon, Haryana, 122015 | Phone 0124 - 4307906, Fax 0124 - 4278596 | Email: contact@molq.in

2015 Sep 15;121(18):3212-3220. PMID: 26096453

41. Vyse et al. Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. *Signal Transduct Target Ther.* 2019;4:5. PMID: 30854234
42. Yi et al. A comparison of epidermal growth factor receptor mutation testing methods in different tissue types in non-small cell lung cancer. *Int J Mol Med.* 2014 Aug;34(2):464-74. PMID: 24891042
43. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215310s002lbl.pdf
44. <https://investors.cullinanoncology.com/news-releases/news-release-details/fda-grants-breakthrough-therapy-designation-cullinan-oncologys>
45. <https://www.prnewswire.com/news-releases/fda-grants-breakthrough-therapy-designation-for-dizal-pharmaceuticals-dzd9008-inpatients-with-locally-advanced-or-metastatic-non-small-cell-lung-cancer-harboring-egfr-exon20-insertion-301469692.html>
46. Madic et al. EGFR C797S, EGFR T790M and EGFR sensitizing mutations in non-small cell lung cancer revealed by six-color crystal digital PCR. *Oncotarget.* 2018 Dec 21;9(100):37393-37406. PMID: 30647840
47. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208065s027lbl.pdf
48. Niederst et al. The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies. *Clin. Cancer Res.* 2015 Sep 1;21(17):3924-33. PMID: 25964297
49. Wang et al. Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance. *J Thorac Oncol.* 2017 Nov;12(11):1723-1727. PMID: 28662863
50. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761210s002lbl.pdf
51. <https://www.genprex.com/news/genprex-receives-u-s-fda-fast-track-designation-for-gene-therapy-that-targets-lung-cancer/>
52. <https://investors.blackdiamondtherapeutics.com/news-releases/news-release-details/black-diamond-therapeutics-granted-fasttrack-designation-fda>

APPENDIX 1: TEST METHODOLOGY

Method

Circulating cell-free total nucleic acid (cfTNA) were isolated from samples using the MagMAX Cell-Free Total Nucleic Acid Isolation Kit. After quality check the isolated and purified sample was directly loaded on Ion Torrent Genexus Next Generation Sequencer and subjected to automated library preparation and template preparation followed by sequencing at average depth of ~35000X.

It utilizes unique molecular tags to enable high sensitivity detection of variants. Analysis is done using Ion Torrent Reporter Software, the data is visualized on Integrative Genomics Viewer (IGV) and analyzed. The final report is generated using OncoPrint curated knowledgebase reporter and includes clinical trials information continuously being updated for the best of the patient management as per clinical guidelines.

DISCLAIMER

- This report was generated using the materials and methods as recommended which required the use of quality reagents, protocols, instruments, software, databases and other items, some of which were provided or made accessible by third parties. A defect or malfunction in any such reagents, protocols, instruments, software, databases and/or other items may compromise the quality or accuracy of the report.
- The report has been created based on, or incorporated inferences to, various scientific manuscripts, references, and other sources of information, including without limitation manuscripts, references, and other sources of information that were prepared by third parties that describe correlations between certain genetic mutations and particular diseases (and/or certain therapeutics that may be useful in ameliorating the effects of such diseases). Such information and correlations are subject to change over time in response to future scientific and medical findings. MolQ Laboratory makes no representation or warranty of any kind, expressed or implied, regarding the accuracy of the information provided by or contained in such manuscripts, references, and other sources is later determined to be inaccurate, the accuracy and quality of the Report may be adversely impacted. MolQ Laboratory is not obligated to notify you of any of the impact that future scientific or medical findings may have on the report.
- The report must always be interpreted and considered within the clinical context, and a physician should always consider the report along with all other pertinent information and data that a physician would prudently consider prior to providing a diagnosis or developing and implementing a plan of care for the patient. The report should never be considered or relied upon alone in making any diagnosis or prognosis. The manifestations of many diseases are caused by more than one gene variant, a single gene variant may be relevant to more than one disease, and certain relevant gene variants may not have been considered in the report. In addition, many diseases are caused or influenced by modifier genes, epigenetic factors, environmental factors, and other variables that are not addressed by the report. This report is based on a Next Generation Assay which does not distinguish between a somatic and a germline variant. If germline variant is in question, further testing is recommended. The report provided by MolQ Laboratory is on a "as is" basis. MolQ Laboratory makes no representation or warranty of any kind, expressed or implied, regarding the report. In no event will MolQ Laboratory be liable for any actual damages, indirect damages, and/or special or consequential damages arising out of or in any way connected with the Report, your use of the report, your reliance on the report, or any defect or inaccurate information included within the report.
- Medical knowledge and annotation are constantly updated and reflects the current knowledge at the time.
- Due to inherent technology limitations of the assay, not all bases of the exome can be covered by this test. Accordingly, variants in regions of insufficient coverage may not be identified and/or interpreted. Therefore, it is possible that certain variants are present in one or more of the genes analyzed, but have not been detected. The variants not detected by the assay that was performed may/ may not impact the phenotype.
- It is also possible that a pathogenic variant is present in a gene that was not selected for analysis and/or interpretation in cases where insufficient phenotypic information is available.
- The report shall be generated within turnaround time (TAT), however, such TAT may vary depending upon the complexity of test(s) requested. MolQ Laboratory under no circumstances will be liable for any delay beyond afore mentioned TAT.
- It is hereby clarified that the report(s) generated from the test(s) do not provide any diagnosis or opinion or recommends any cure in any manner. MolQ Laboratory hereby recommends the patient and/or the guardians of the patients, as the case may be, to take assistance of the clinician or a certified physician or doctor, to interpret the report(s) thus generated. MolQ Laboratory hereby disclaims all liability arising in connection with the report(s).
- In a very few cases genetic test may not show the correct results, e.g. because of the quality of the material provided to MolQ Laboratory. In case where any test provided by MolQ Laboratory fails for unforeseeable or unknown reasons that cannot be

influenced by MolQ Laboratory in advance, MolQ Laboratory shall not be responsible for the incomplete, potentially misleading or even wrong result of any testing if such could not be recognized by MolQ Laboratory in advance.

- This is a laboratory developed test and the development and the performance characteristics of this test was determined by reference laboratory as required by the CLIA 1988 regulations. The report, and the tests used to generate the Report have not been cleared or approved by the US Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The test results have scientifically shown to be clinically useful.

APPENDIX 2: GENE LIST WITH COVERAGE

DNA Hotspots					
<i>AKT1</i>	<i>AKT2</i>	<i>AKT3</i>	<i>ALK</i>	<i>AR</i>	<i>ARAF</i>
<i>BRAF</i>	<i>CDK4</i>	<i>CDKN2A</i>	<i>CHEK2</i>	<i>CTNNB1</i>	<i>EGFR</i>
<i>ERBB2</i>	<i>ERBB3</i>	<i>ERBB4</i>	<i>ESR1</i>	<i>FGFR1</i>	<i>FGFR2</i>
<i>FGFR3</i>	<i>FGFR4</i>	<i>FLT3</i>	<i>GNA11</i>	<i>GNAQ</i>	<i>GNAS</i>
<i>HRAS</i>	<i>IDH1</i>	<i>IDH2</i>	<i>KIT</i>	<i>KRAS</i>	<i>MAPK1</i>
<i>MAPK2</i>	<i>MET</i>	<i>MTOR</i>	<i>NRAS</i>	<i>NTRK1</i>	<i>NTRK2</i>
<i>NTRK3</i>	<i>PDGFRA</i>	<i>PIK3CA</i>	<i>PTEN</i>	<i>RAF1</i>	<i>RET</i>
<i>ROS1</i>	<i>SMO</i>	<i>TP53</i>			
CNVs					
<i>ALK</i>	<i>AR</i>	<i>CD274</i>	<i>CDKN2A</i>	<i>EGFR</i>	<i>ERBB2</i>
<i>ERBB3</i>	<i>FGFR1</i>	<i>FGFR2</i>	<i>FGFR3</i>	<i>KRAS</i>	<i>MET</i>
<i>PIK3CA</i>	<i>PTEN</i>				
Inter-genetic Fusions					
<i>ALK</i>	<i>BRAF</i>	<i>ESR1</i>	<i>FGFR1</i>	<i>FGFR2</i>	<i>FGFR3</i>
<i>MET</i>	<i>NRG1</i>	<i>NTRK1</i>	<i>NTRK2</i>	<i>NTRK3</i>	<i>NUTM1</i>
<i>RET</i>	<i>ROS1</i>	<i>RSPO2</i>	<i>RSPO3</i>		
Intra-genetic Fusions					
<i>AR</i>	<i>EGFR</i>	<i>MET</i>			